- Home
- THC vs RPRX Comparison
THC vs RPRX Comparison
Compare THC & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | THC | RPRX |
|---|---|---|
| Founded | 1967 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7B | 16.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | THC | RPRX |
|---|---|---|
| Price | $210.07 | $39.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 3 |
| Target Price | ★ $222.00 | $46.00 |
| AVG Volume (30 Days) | 1.0M | ★ 4.3M |
| Earning Date | 10-28-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 2.21% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 14.57 | 1.75 |
| Revenue | ★ $20,846,000,000.00 | $2,349,844,000.00 |
| Revenue This Year | $3.98 | $37.13 |
| Revenue Next Year | $4.39 | $1.48 |
| P/E Ratio | ★ $14.41 | $22.68 |
| Revenue Growth | N/A | ★ 3.70 |
| 52 Week Low | $109.82 | $24.05 |
| 52 Week High | $222.82 | $41.24 |
Technical Indicators
Market Signals| Indicator | THC | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.74 | 57.50 |
| Support Level | $209.06 | $39.24 |
| Resistance Level | $222.82 | $40.50 |
| Average True Range (ATR) | 6.32 | 0.91 |
| MACD | 0.88 | -0.08 |
| Stochastic Oscillator | 65.17 | 76.02 |
Price Performance
Historical ComparisonAbout THC Tenet Healthcare Corporation
Tenet Healthcare is a Dallas-based healthcare services organization. It operates acute and specialty hospitals (47 as of December 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the US, primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.